Deferoxamine NEW
| Price | $64 | $172 | $269 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Deferoxamine | CAS No.: 70-51-9 |
| Purity: 99.97% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Deferoxamine |
| Description | Deferoxamine（Desferrioxamine B） is an iron chelator (binds Fe(III) and many other metal cations) that inhibits neuronopathy, may be used to modify the reduction of iron accumulation and deposition in tissues, and may improve neurological dysfunction by inhibiting ferroptosis and neuroinflammation following traumatic brain injury.Desferrioxamin-B has antioxidant, antiproliferative, Deferoxamine has antioxidant, antiproliferative, and antitumor activities, and can induce HIF-1α production, apoptosis and autophagy in cancer cells.Desferrioxamin-B can be used in the treatment of acute iron toxicity and COVID-19 related diseases. |
| In vitro | Deferoxamine (1 mM; 16 hours or 4 weeks) improves HIF-1α function under hypoxic and hyperglycemic conditions and reduces ROS in MEF cells.[1] Deferoxamine mesylate (100 μM; 24 h) increases InsR expression and activity and induces increased p-Akt/total Akt/PKB levels.[2] Deferoxamine (5, 10, 25, 50, 100 μM; 7 or 9 days) inhibits the proliferation of tumor-associated MSCs and bone marrow MSCs.[3]. Deferoxamine (5, 10, 25, 50, 100 μM; 7 days) induces apoptosis in mesenchymal stem cells.[3] Deferoxamine (10 μM; 3 days) affects the expression of mesenchymal stem cell adhesion proteins[3] Deferoxamine (100 μM; 24 h) induces autophagy-mediated by HIF-1α levels in SH-SY5Y cells.[4] |
| In vivo | Deferoxamine (6.57 μg/mouse; drip; once daily for 21 days) promotes wound healing and increases neovascularization in aged or diabetic mice.[1] Deferoxamine (200 mg/kg; i.p.; once daily for 2 weeks) causes HIF-1α stabilization and increases glucose uptake, hepatic InsR expression, and signaling in vivo.[2] |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 10 mg/mL (17.84 mM), Sonication is recommended. H2O : 7.14 mg/mL (12.73 mM) |
| Keywords | Deferoxamine |
| Inhibitors Related | Stavudine | Sodium 4-phenylbutyrate | L-Ascorbic acid | Hydroxychloroquine | Guanidine hydrochloride | Tributyrin | Paeonol | Naringin |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Approved Drug Library | EMA Approved Drug Library | Autophagy Compound Library | Drug Repurposing Compound Library | Microbial Natural Product Library | Anti-Cancer Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $64.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $8.00/1mg |
Wuhan Topule Biopharmaceutical Co., Ltd
|
2023-06-13 | ||
| $1.10/1g |
VIP4Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2021-05-25 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY